Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Current Assets (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Current Assets readings, the most recent being $30.9 million for Q4 2024.

  • On a quarterly basis, Current Assets rose 130.97% to $30.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $30.9 million, a 130.97% increase, with the full-year FY2024 number at $30.9 million, up 130.97% from a year prior.
  • Current Assets hit $30.9 million in Q4 2024 for Unicycive Therapeutics, down from $37.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $51.7 million in Q1 2024 to a low of $2.6 million in Q4 2022.
  • Median Current Assets over the past 4 years was $18.6 million (2023), compared with a mean of $23.3 million.
  • Biggest five-year swings in Current Assets: crashed 85.64% in 2022 and later soared 406.77% in 2023.
  • Unicycive Therapeutics' Current Assets stood at $18.4 million in 2021, then crashed by 85.64% to $2.6 million in 2022, then soared by 406.77% to $13.4 million in 2023, then soared by 130.97% to $30.9 million in 2024.
  • The last three reported values for Current Assets were $30.9 million (Q4 2024), $37.7 million (Q3 2024), and $44.1 million (Q2 2024) per Business Quant data.